Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

LightOx

Ownership
Private
Therapeutic Areas
OncologyInfectious DiseasesRheumatology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small moleculesAntibody-drug conjugates (ADCs)Fluorescent probes/drug-like compoundsHDAC inhibitor fusions

LightOx General Information

LightOx has developed a new class of light activated small molecule therapeutics designed to selectively target and kill cancer cells upon exposure to light. Their lead candidates are formulated for topical treatment of oral cancers. The company’s approach allows minimal off-target toxicity and the potential for joint diagnostic-treatment agents. Lead programs are preclinical; no clinical results have been published yet.

Contact Information

Website
https://lightox.co.uk/
Primary Industry
Biotech
Corporate Office
Newcastle upon Tyne, England
United Kingdom

Drug Pipeline

LXD191
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to LightOx's pipeline data

Book a demo

Key Partnerships

Merck – distribution deal for research tools under Research Use Only model.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

LightOx Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view LightOx's complete valuation and funding history, request access »

LightOx Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals